Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep 20;22(18):10149.
doi: 10.3390/ijms221810149.

Biomarkers for Ehlers-Danlos Syndromes: There Is a Role?

Laura Caliogna  1 , Viviana Guerrieri  1 , Salvatore Annunziata  1 , Valentina Bina  2 , Alice Maria Brancato  1 , Alberto Castelli  1 , Eugenio Jannelli  1 , Alessandro Ivone  1 , Federico Alberto Grassi  1 , Mario Mosconi  1 , Gianluigi Pasta  1
Affiliations
Review

Biomarkers for Ehlers-Danlos Syndromes: There Is a Role?

Laura Caliogna et al. Int J Mol Sci. .

Abstract

Ehlers-Danlos syndromes (EDS) are an inherited heterogeneous group of connective tissue disorders characterized by an abnormal collagen synthesis affecting skin, ligaments, joints, blood vessels, and other organs. It is one of the oldest known causes of bruising and bleeding, and it was described first by Hippocrates in 400 BC. In the last years, multiple gene variants involved in the pathogenesis of specific EDS subtypes have been identified; moreover, new clinical diagnostic criteria have been established. New classification models have also been studied in order to differentiate overlapping conditions. Moreover, EDS shares many characteristics with other similar disorders. Although distinguishing between these seemingly identical conditions is difficult, it is essential in ensuring proper patient care. Currently, there are many genetic and molecular studies underway to clarify the etiology of some variants of EDS. However, the genetic basis of the hypermobile type of EDS (hEDS) is still unknown. In this review, we focused on the study of two of the most common forms of EDS-classic and hypermobile-by trying to identify possible biomarkers that could be of great help to confirm patients' diagnosis and their follow up.

Keywords: Ehlers-Danlos syndrome; biomarkers; diagnosis; follow up.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Parapia L.A., Jackson C. Ehlers-Danlos Syndrome—A Historical Review. Br. J. Haematol. 2008;141:32–35. doi: 10.1111/j.1365-2141.2008.06994.x. - DOI - PubMed
    1. Malfait F., Francomano C., Byers P., Belmont J., Berglund B., Black J., Bloom L., Bowen J.M., Brady A.F., Burrows N.P., et al. The 2017 International Classification of the Ehlers-Danlos Syndromes. Am. J. Med. Genet. C Semin. Med. Genet. 2017;175:8–26. doi: 10.1002/ajmg.c.31552. - DOI - PubMed
    1. Byers P.H., Belmont J., Black J., De Backer J., Frank M., Jeunemaitre X., Johnson D., Pepin M., Robert L., Sanders L., et al. Diagnosis, Natural History, and Management in Vascular Ehlers-Danlos Syndrome. Am. J. Med. Genet. C Semin. Med. Genet. 2017;175:40–47. doi: 10.1002/ajmg.c.31553. - DOI - PubMed
    1. Chiarelli N., Ritelli M., Zoppi N., Colombi M. Cellular and Molecular Mechanisms in the Pathogenesis of Classical, Vascular, and Hypermobile Ehlers‒Danlos Syndromes. Genes. 2019;10:E609. doi: 10.3390/genes10080609. - DOI - PMC - PubMed
    1. Remvig L., Duhn P.H., Ullman S., Kobayasi T., Hansen B., Juul-Kristensen B., Jurvelin J.S., Arokoski J. Skin Extensibility and Consistency in Patients with Ehlers-Danlos Syndrome and Benign Joint Hypermobility Syndrome. Scand. J. Rheumatol. 2009;38:227–230. doi: 10.1080/03009740802520714. - DOI - PubMed

MeSH terms